SiNtx Technologies Inc (SINT)

[boston745]

The base concept is Zimmer Biomet paid an entity $2.5m. That entity then invested those funds with Dr Bal's investment company which was then loaned those funds to Sintx. It was a clever way to get funds to Sintx from Zimmer using a pre-established agreement. The loan was used a bridge loan to help protect Sintx core IP once the Hercules loan was paid off. Hercules loan had first rights to Sintx core IP with Dr Bal's investment company having second place rights. Once Hercules loan was paid off, the investment company had first rights to Sintx IP until CTL closed. Now CTL has first rights to acquire Sintx IP working as a Crown Jewel defense. CTL rights to Sintx core IP expires in 2028 unless a new contract is signed.

I think this needs to be explored some more. Shortly after Sintx went public it got a loan from Hercules which used Sintx IP as collateral. Then as the Hercules loan was coming to its end, being paid off, a new loan with the IP as collateral was issued using the aforementioned $2.5m which i believe originated from Zimmer Biomet. That loan worked as a bridge securing the assets between the close of the Hercules loan and the time the deal with CTL closed. Thus, almost since the moment this company went public it has gone through enormous effort to protect the core IP. Really take that in and review this quote when factoring in that the $2.5m likely originated from Zimmer Biomet showing Zimmer Biomet was involved in helping secure Sintx core IP.

AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.

We are a small company where everybody is invested in this business. Theres a lot of future potential for the company and everybody has to have bought in on that in the sense that they believe that there is potential for long term success for the company. I think the biggest area of excitement is the opportunity to transform people's lives using Silicon Nitride. We call it the Ideal Biomaterial.

Quote Sources:
https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1
https://vimeo.com/655106005

========================================

Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.

https://www.mdpi.com/2571-6131/4/2/16/htm


========================================

We disagree on what is success here, so I don't know how you can continue to say I support Anson's efforts to distort

There is no way to look at it where you dont see R&D as a success. Theyve gone from having product candidates for a 64bn market to several markets close to 300bn in aggregate. They successfully imbued fabrics and plastics with Si3n4 while enhancing those products with Si3n4's beneficial properties. They may not succeed in bringing every product to market but just one of those major markets represents another layer of success.
Based on what you've said in the past, nothing to you is a success unless two things happen. Commercialization agreements leading to growing revenue and growing stockprice.
Those have not happened...YET! That means they could happen. However, your statement went further than that by claiming they havent succeeded at anything other then securing funding for their paychecks. As we have had this debate before, youve been here for 8 years now, you know theyve succeeded at developing several product candidates. Thats a success, just not the level of success you want to see. It has value, just not value reflected by the markets...YET! Regardless its success in R&D. Now they need to succeed at transitioning to market which brings its own set of challenges. So yes you belong grouped with Anson's wolfpack because you continue to distort the facts.